CANDEL THERAPEUTICS APPOINTS PHARMA VETERAN AND IMMUNOLOGIST PAUL-PETER TAK, M.D., PH.D., AS CHIEF EXECUTIVE OFFICER; EXPANDS LEADERSHIP TEAM WITH CHIEF FINANCIAL OFFICER, CHIEF BUSINESS OFFICER AND CHIEF REGULATORY OFFICER APPOINTMENTS

– Advancing oncolytic viral immunotherapies that light up and destroy local tumors, while creating a durable and systemic immune response
– Phase 3 prostate cancer program enrolling patients, clinical data readouts from other ongoing clinical programs in 2021
– Company founder and former CEO Estuardo Aguilar-Cordova, M.D. inf., Ph.D., takes on role of chief scientific officer
– Nathan Caffo named chief business officer; John Canepa appointed as chief financial officer; Susan Stewart named chief regulatory officer